Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atumelnant - Crinetics Pharmaceuticals

Next Previous
Drug Profile

Atumelnant - Crinetics Pharmaceuticals

Alternative Names: CRN 04894

Latest Information Update: 27 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crinetics Pharmaceuticals
  • Class Amides; Antineoplastics; Antisecretories; Benzene derivatives; Cyclobutanes; Ethers; Fluorocarbons; Ketones; Piperazines; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action Melanocortin type 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Congenital adrenal hyperplasia
  • Phase II Cushing syndrome
  • No development reported Ectopic ACTH syndrome

Most Recent Events

  • 27 Feb 2026 Crinetics Pharmaceuticals completes a phase I trial (In volunteers) in USA (PO, Tablet) (NCT07221084)
  • 06 Jan 2026 Pharmacodynamics and adverse events data from the phase II TouCAHn trial in Congenital adrenal hyperplasia released by Crinetics Pharmaceuticals
  • 11 Dec 2025 Phase-III clinical trials in Congenital adrenal hyperplasia in Australia (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top